Titus B. Ball

CIK: 0001675628

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)8 (80.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (20.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ONC

BeOne Medicines Ltd.

Officer

Discretionary Trading P&L

Holdings

Transaction History (10 total)

ONC
BeOne Medicines Ltd.
Sep 1, 2026
Sale(S)
Direct
132 shares at avg. $355.86$47K
ONC
BeOne Medicines Ltd.
Jun 11, 2026
Award(A)
Direct
31.2K shares-
ONC
BeOne Medicines Ltd.
Jun 11, 2026
Sale(S)
Direct
49 shares at avg. $256.39$13K
ONC
BeOne Medicines Ltd.
Jun 11, 2026
Sale(S)
Direct
120 shares at avg. $257.53$31K
ONC
BeOne Medicines Ltd.
Jun 8, 2026
Sale(S)
Direct
36 shares at avg. $272.08$10K
ONC
BeOne Medicines Ltd.
Jun 8, 2026
Sale(S)
Direct
100 shares at avg. $271.06$27K
ONC
BeOne Medicines Ltd.
Sep 2, 2025
Sale(S)
Direct
122 shares at avg. $326.76$40K
ONC
BeOne Medicines Ltd.
Jun 11, 2025
Sale(S)
Direct
134 shares at avg. $258.36$35K
ONC
BeOne Medicines Ltd.
Jun 10, 2025
Award(A)
Direct
29.6K shares-
BGNE
BeiGene, Ltd.
Sep 3, 2024
Sale(S)
Direct
137 shares at avg. $189.94$26K

		Type	Shares	Price		Ownership
Sep 1, 2026	ONC BeOne Medicines Ltd.	Sale(S)	132	$355.86	$46,974	Direct
Jun 11, 2026	ONC BeOne Medicines Ltd.	Award(A)	31,213	-	$0	Direct
Jun 11, 2026	ONC BeOne Medicines Ltd.	Sale(S)	49	$256.39	$12,563	Direct
Jun 11, 2026	ONC BeOne Medicines Ltd.	Sale(S)	120	$257.53	$30,904	Direct
Jun 8, 2026	ONC BeOne Medicines Ltd.	Sale(S)	36	$272.08	$9,795	Direct
Jun 8, 2026	ONC BeOne Medicines Ltd.	Sale(S)	100	$271.06	$27,106	Direct
Sep 2, 2025	ONC BeOne Medicines Ltd.	Sale(S)	122	$326.76	$39,865	Direct
Jun 11, 2025	ONC BeOne Medicines Ltd.	Sale(S)	134	$258.36	$34,620	Direct
Jun 10, 2025	ONC BeOne Medicines Ltd.	Award(A)	29,601	-	-	Direct
Sep 3, 2024	BGNE BeiGene, Ltd.	Sale(S)	137	$189.94	$26,022	Direct

1-10 of 10 transactions

About Ball Titus B.

Ball Titus B. (SEC CIK 0001675628) files insider reports with the SEC as Principal Accounting Officer of BeOne Medicines Ltd. (ONC).

Signal8 holds 6 ownership filings by Ball Titus B., all Form 4s, filed between Sep 5, 2024 and Sep 3, 2026. Those filings report 10 transactions, from Sep 3, 2024 to Sep 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Ball Titus B.'s filings is in BASEL.

Recent filings by Ball Titus B.

Sep 1, 2026: Open-market sale of ONC shares (Form 4, code S).
Jun 11, 2026: Grant or award of ONC shares (Form 4, code A).
Jun 11, 2026: Open-market sales of ONC shares (2 lines, Form 4, code S).
Jun 8, 2026: Open-market sales of ONC shares (2 lines, Form 4, code S).
Sep 2, 2025: Open-market sale of ONC shares (Form 4, code S).

Other insiders filing for BeOne Medicines Ltd. (ONC)

Wang Xiaodong, Director
Lee Chan Henry, SVP, General Counsel
Wu Xiaobin, President and COO
OYLER JOHN, Chief Executive Officer
Rosenberg Aaron, Chief Financial Officer
Wang Lai, President, Global Head of R&D

How to read Form 4 transaction codes